Skip to main content
Clinical Trials/NCT05589103
NCT05589103
Recruiting
Not Applicable

Mild Head Trauma in the Emergency Room: Assessment of the Risk of Intracranial Hemorrhage in Patients Receving Platelet Inhibitors.

University Hospital, Strasbourg, France1 site in 1 country1,692 target enrollmentJanuary 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head Trauma Injury
Sponsor
University Hospital, Strasbourg, France
Enrollment
1692
Locations
1
Primary Endpoint
Propensity score on the factors influencing the taking of antiplatelet agents.
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The clinical signs presented by a patient with a mild head injury are highly variable but remain strongly predictive of brain damage. The reference examination for the diagnosis of post-traumatic intracranial hemorrhage is currently the cerebral scanner without injection of contrast medium. Magnetic resonance imaging (MRI) tends to surpass CT in equipped centers, except for suspected bone lesions. The time required to perform brain imaging depends on the patient's clinical condition, comorbidities and treatments.

The responsibility of antiplatelet agents in post-traumatic intracranial hemorrhage is currently discussed, particularly with aspirin.

The hypothesis is that there is no significant difference in the proportion of intracranial hemorrhage in patients on antiplatelet agents after mild head trauma, in the absence of other factors favoring the occurrence of intracranial hemorrhage.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
December 31, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Strasbourg, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Propensity score on the factors influencing the taking of antiplatelet agents.

Time Frame: Files analysed retrospectively from January 01, 2017 to December 31, 2017 will be examined

Study Sites (1)

Loading locations...

Similar Trials